Previous investigations showed greater efficacy of ATMi/radiation or ATMi/doxorubicin in TP53-mutant cancers compared to TP53-WT6,53,54, possibly because when p53 is absent, ATM is required for cell cycle arrest following DNA damage53. This evidence concerns the gene ATM and cancer.